Related Experiment Video

Updated: May 2, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.7K

Pancreatic cancer: current standards, working towards a new therapeutic approach

Olugbenga Olowokure1, Xiaoyang Qi

  • 1University of Cincinnati - Hematology-Oncology, Internal Medicine, The Vontz Center for Molecular Studies 3125 Eden Avenue, Cincinnati, OH 45267-0508, USA.

Expert Review of Anticancer Therapy
|March 14, 2014
PubMed

Insights

A novel biotherapeutic agent, Saposin C-dioleoylphosphatidylserine (SapC-DOPS) nanovesicles, shows promise for pancreatic cancer treatment. Targeting the phosphatidylserine biomarker on cancer cells, this approach demonstrates strong preclinical efficacy and safety.

Area of Science:

  • Oncology
  • Nanomedicine
  • Biochemistry

Background:

  • Pancreatic cancer presents a significant clinical challenge with low survival rates.
  • Existing therapeutic strategies for pancreatic cancer are limited.
  • There is a critical need for novel treatment approaches.

Discussion:

  • Saposin C-dioleoylphosphatidylserine (SapC-DOPS) nanovesicles represent a new biotherapeutic agent for pancreatic cancer.
  • These nanovesicles leverage Saposin C (SapC) and dioleoylphosphatidylserine (DOPS) to form stable nanoparticles.
  • Phosphatidylserine (PS) on pancreatic cancer cell membranes serves as a target for cancer-selective therapy.

Key Insights:

  • SapC-DOPS nanovesicles effectively target cancer cells by recognizing the phosphatidylserine biomarker.
  • Preclinical studies indicate excellent therapeutic efficacy of SapC-DOPS nanovesicles.
  • The biotherapeutic agent exhibits a favorable safety profile in preclinical evaluations.

Outlook:

  • The promising preclinical data suggest SapC-DOPS nanovesicles are a viable option for pancreatic cancer therapy.
  • Further clinical development of this nanovesicle-based approach is warranted.
  • This strategy offers a potentially improved treatment modality for pancreatic cancer patients.

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

1.1K
An Orthotopic Resectional Mouse Model of Pancreatic Cancer07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

11.2K

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
563
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.2K